January 10th, 2022 | 12:02 CET
Trading stocks in focus: Aspermont, BASF, BioNTech
At the beginning of the week, the DAX is currently trading around 0.19% down at 15,939 points and thus remains below the psychological mark of 16,000 points. The MDAX recently traded again below the 35,000 mark at 34,804 points (-0.52%), TexDAX at 3,653 points (-1.50%) and SDAX at 15,936 points with 1.06% in the red. Overall, the indices had given back their initial gains from the start of trading and are trading in negative territory in the morning.
time to read: 1 minutes
|
Author:
Mario Hose
ISIN:
ASPERMONT LTD | AU000000ASP3 , BASF SE NA O.N. | DE000BASF111 , BIONTECH SE SPON. ADRS 1 | US09075V1026
Table of contents:
Author
Mario Hose
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Tag cloud
Shares cloud
Most traded companies
The share of BioNTech is currently with over 2,000 trades at the level of 188.00 EUR and a change of +0.99% on Tradegate the most frequently traded stock. The BASF share comes to over 1,100 trades and is thus at the DAX top of the most traded companies. The value of the chemical giant's stock loses about 0.09% to EUR 66.03.
Announcement of the company raises interest
Aspermont's stock is up 11.4% today and last traded at EUR 0.0156. The B2B media market leader with a home exchange in Australia is in the focus of investors today, as a corporate announcement reported a collaboration with Asian investment advisory firm Soochow CSSD Capital Markets. Under the collaboration, Soochow has the option to purchase up to 250 million shares at a price of AUD 0.0432 until the end of September 2022. The collaboration is performance-based with the stock options. The shares closed at AUD 0.025 on the ASX, the company's home exchange, today.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
In this respect, there is a concrete conflict of interest in the reporting on the companies.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is also a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
